<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19266087</article-id><article-id pub-id-type="pmc">2648638</article-id><article-id pub-id-type="doi">10.1155/2008/212067</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcome in 33 Patients in a Tertiary Care Center</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farhat</surname><given-names>Mirna H.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shamseddine</surname><given-names>Ali I.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barada</surname><given-names>Kassem A.</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Riad El-Solh, Beirut 1107 2020, Lebanon</aff><aff id="I2"><sup>2</sup>Division of Gastroenterology, Department of Internal Medicine, American University of Beirut, Riad El-Solh, Beirut 1107 2020, Lebanon</aff><author-notes><corresp id="cor1">*Kassem A. Barada: <email>kb02@aub.edu.lb</email></corresp><fn fn-type="other"><p>Recommended by Masatoshi Kudo</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>2</day><month>12</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>212067</elocation-id><history><date date-type="received"><day>20</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Mirna H. Farhat et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Introduction</italic>. Small bowel cancers are rare. Accumulation of data regarding their clinical presentation, pathologic features, prognostic factors, treatment modalities, and outcome is difficult. <italic>Methods</italic>. This is a retrospective study of the medical records of 33 patients with small bowel cancers treated at the American University of Beirut-Medical Center over a 20-year period. <italic>Results</italic>. The study included 25 males (76%) and 8 females (24%). Median age at presentation was 56 years. Most common symptoms were abdominal pain (66.7%) and weight loss (57.6%). Thirteen patients presented with abdominal emergencies (39.3%). Lymphoma was the most common malignant tumor (36.4%), followed by adenocarcinoma (33.3%), leiomyosarcoma (15.2%), gastrointestinal stromal tumors (12.1%), and neuroendocrine tumors (3.0%). Tumors were located in the duodenum in 30% of patients, jejunum in 33%, and ileum in 36%. Resectability rate was 72.7% and curative R0 resection was achieved in 54.1% (13/24) of patients. 5-year survival of the 33 patients was 24.2%. <italic>Conclusion</italic>. Small bowel cancers are difficult to diagnose because of the nonspecific symptoms. Most patients present with advanced disease and have poor prognosis. Adenocarcinoma and duodenal location have the worst 5-year survival in contrast to stromal tumors and those with ileal location which have the best survival.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Small bowel cancers are uncommon tumors of thegastrointestinal tract. As a result of their infrequency and variety, theaccumulation of data regarding their clinical presentation, pathologicfeatures, prognostic factors, treatment modalities, and outcome has beendifficult.</p><p>This study wasconducted to review the experience with small bowel tumors of 33 patients seenat the American University of Beirut Medical Center.</p></sec><sec sec-type="section" id="sec2"><title>2. Patients and Methods</title><p>During a 20-year period (1986&#x02013;2006), 33patients were treated for small bowel tumors at the American University ofBeirut Medical Center. Approval was obtained from the Institutional ResearchBoard. Data obtained from the medicalrecords were gathered regarding standard demographic data, presenting signs andsymptoms, comorbid medical illnesses, diagnostic workup, operative procedures,pathologic diagnosis, and subsequent follow-up visits to document therecurrence of previous or subsequent associated primary cancers. Recurrence wasdefined as biopsy-proven tumor or radiologic evidence of obvious local ordistant recurrence.</p><p>Periampullary tumors, secondary, and benign tumors of thesmall bowel were excluded. Staging of patients was done according to the TNMclassification system and AJCC for small bowel tumors [<xref ref-type="bibr" rid="B1">1</xref>], except for lymphomas.</p><p>Survival durationwas measured from the time of diagnosis to the last follow-up evaluation ordeath. Follow-up data was obtained from patient medical records or fromtelephone interviews with the patient or family members. Follow-up data wasavailable on 30 out of 33 patients.</p><p>All data was coded and enteredusing &#x0201c;SPSS 15.0&#x0201d; computer program.</p></sec><sec sec-type="section" id="sec3"><title>3. Results</title><sec id="subsec3.1"><title>3.1. Demographic Data</title><p>Thisstudy included 33 patients with histologically confirmed small bowelmalignancies. They were 25 males (76%) and 8 females (24%) patients. The maleto female ratio was 3.1:1 with a median age at presentation of 56 years (range:23&#x02013;77).  Two-thirds of the patients were older than 50years (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>There was ahistory of Crohn's disease in one patient, ulcerative colitis in another one,and celiac disease in a third one. One-third of the patients were smokers(11/33). Three patients (9.1%) had a history of another primary malignancy(mucinous cystadenocarcinoma of ovary, biopsy-proven cholangiocarcinoma, andleiomyosarcoma of the thigh).</p><p>Most complaintswere nonspecific and these included in decreasing order abdominal pain (66.7%),weight loss (57.6%), followed by nausea and vomiting (27%) (see <xref ref-type="table" rid="tab1">Table 1</xref>).  Thirteen patients presented with emergenciessuch as bowel obstruction (<italic>n</italic> = 8, 24%) and bowel perforation (<italic>n</italic> = 4, 12%). Of thefour patients that had perforation, three had lymphomas and one hadleiomyosarcoma. Acute abdomen was the initial presentation in four patients(12%).</p><p>Endoscopy wasperformed on 10 out of 33 patients. It detected the tumor in 7 only (6duodenum, 1 ileum) and it failed to detect the disease in 3 patients, all ofwhich had ileal disease. Upper GI series was performed on 12 out of 33patients. The disease was detected in 11 patients (4 jejunum, 6 duodenum, 1ileum) and missed in one patient having a tumor in the ileum.</p><p>Computedtomography was used in 13/33 patients and emergent laparatomy in 4/33.</p></sec><sec id="subsec3.2"><title>3.2. Characteristics of the Tumors</title><p>Fourdifferent histologic types of tumors were identified.  Lymphoma was the most common tumor (36.4%),followed by adenocarcinoma (33.3%), leiomyosarcoma (15.2%), gastrointestinalstromal tumors (GISTs) (12.1%), or neuroendocrine tumors (3.0%) (see <xref ref-type="table" rid="tab2">Table 2</xref>).</p><p>					<xref ref-type="table" rid="tab2">Table 2</xref> showsthe anatomical distribution of the tumors with respect to histology. The tumorwas located in the duodenum in 30% of patients, jejunum in 33%, and ileum in36%.  Most adenocarcinomas were locatedin the duodenum (7/10), in contrast to most lymphomas (10/12) and allleiomyosarcomas (5/5) that were located in the jejunum and ileum.</p></sec><sec id="subsec3.3"><title>3.3. Treatment</title><p>Surgicalresection was carried out in 24 out of 33 patients. Resectability rate was 72.7%and R0 resection was achieved in 54.1% (13/24) of patients (see <xref ref-type="table" rid="tab3">Table 3</xref>). Twopatients underwent palliative double bypass surgery. Four patients were deemedunresectable because of peritoneal metastasis, locally advanced disease, andvascular invasion. The surgical procedures performed are listed in <xref ref-type="table" rid="tab4">Table 4</xref>. There were four cases of tumor recurrence.</p><p>Reoperation wasperformed in 5 patients for the following reasons: tumor recurrence,metastasis, and postoperative complications. Emergent laparatomy was performedin 4 patients (3 lymphoma and 1 leiomyosarcoma). Chemotherapy was administeredto 13 patients (39.3%).</p></sec><sec id="subsec3.4"><title>3.4. Tumor Characteristics</title><p>Tumor size wasavailable on 27 patients. Sixteen patients (59%) had tumors greater than 5 cm,8 patients (30%) had tumors less than 3 cm, and 3 patients (11%) had tumorsizes between 3 and 5 cm.</p><p>Tumor grade was available for 12 patients (36.4%). Among the 12 patients, 8 patients (66.7%) had wellor moderately differentiated tumors and 4 had poorly differentiated tumors (33.3%) (see <xref ref-type="table" rid="tab5">Table 5</xref>).</p><p>TNM staging was available on 26patients (78.7%). According to AJCC staging of small bowel malignancies (<xref ref-type="table" rid="tab5">Table 5</xref>), tumors in our study were classified as stage I (<italic>n</italic> = 2), stage II (<italic>n</italic> = 9), stageIII (<italic>n</italic> = 8), stage IV (<italic>n</italic> = 7) (see <xref ref-type="table" rid="tab6">Table 6</xref>). Almost half of the patients presentedwith metastatic disease (stage III/IV). Lymph nodes (10/33) were the mostcommon site involved by metastasis followed by the liver (5/33), lung (3/33),brain (1/33), bone (1/33), and omentum (1/33).</p></sec><sec id="subsec3.5"><title>3.5. Survival</title><p>Survivalanalysis of the 33 patients showed that 51.5%, 33.3%, and 24.2% were alive at 1,3, and 5 years, respectively. Three patients were lost to follow-up. Meansurvival rates for the different malignancies were 22.03 months foradenocarcinomas, 52.85 months for lymphomas, 47.6 months for leiomyosarcoma,and 64.9 months for GIST.</p><p>1-, 3-, and 5-year survivals for the different tumor locations and histologies are listed inTables <xref ref-type="table" rid="tab7">7</xref> and <xref ref-type="table" rid="tab8">8</xref>, respectively. However, the number of patients in somecategories was small which could have affected the significance of some ofthese rates.</p></sec></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>Neoplasms of the small intestine are unusual andconstitute less than 3% of all gastrointestinal tract cancers [<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>]. These tumorsare known for their rarity, variability, nonspecific symptomatology, diagnosticdifficulties, delayed presentation, and overall poor prognosis [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Over 90% of cases occur in people over the age of 40 [<xref ref-type="bibr" rid="B5">5</xref>]with a median age at diagnosis of 55 years [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>] and men tend to be moreaffected by the tumors than women [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B8">8</xref>], which is in agreement with ourresults.</p><p>Abdominal pain, weight loss, nausea, and vomiting were themost common presenting symptoms for small bowel tumors in this study, which issimilar to findings reported in previous studies [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. Bleeding is morecommon with carcinomas; perforation is more common with lymphomas, whileobstruction is common to all enteric malignancies [<xref ref-type="bibr" rid="B10">10</xref>]. No distinctpresentation by pathology was evident in our study.</p><p>The lack of symptom specificity in patients suffering fromsmall intestinal malignancies and failure to evaluate the small bowel, which isa blind spot to routine endoscopic and radiological diagnostic tests, have beenconsidered as a contributing factor to the late presentations of the diseaseand eventually the delay in diagnosis [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Histologically, small bowel tumors are of differentsubtypes, with adenocarcinoma being the most frequent (47%) followed bycarcinoid tumors (28%), GI lymphomas (12%), and GI sarcomas (12%) [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. In this study, lymphomas were the most common type, followed byadenocarcinomas, sarcomas, and stromal tumors.</p><p>On average, adenocarcinomas are distributed moreproximally in the small intestine, most frequently in the duodenum followed bythe jejunum and ileum, whereas lymphomas are more common distally, with nearlyequal distribution between the jejunum and the ileum [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. Carcinoidtumors are distributed throughout the small intestines, but are locatedpreponderantly in the ileum. Sarcomas are found most often in the jejunum [<xref ref-type="bibr" rid="B7">7</xref>]. In our study, adenocarcinomas were mostly located in the duodenum, whilesarcomas and lymphomas were mostly located in the more distal parts of thesmall bowel.</p><p>Small bowel tumors were noticed to be associated with anincreased incidence of second malignancies [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. Treadwell and White reported second tumor occurrence in 43% of patients with primary small boweltumors [<xref ref-type="bibr" rid="B4">4</xref>], whereas Ripley and Weinerman noted an 8-fold increase in secondmalignancies with small bowel carcinoma with 73% of the tumors occurring beforethe diagnosis of the small bowel malignancy [<xref ref-type="bibr" rid="B13">13</xref>]. The incidence of a second malignancyapproached 9% in our series.</p><p>Surgical resection remains the cornerstone of therapy forthese malignancies [<xref ref-type="bibr" rid="B11">11</xref>]. Cunningham et al. showed a significantly longer mediansurvival for the resected group (26 months versus 11 months) [<xref ref-type="bibr" rid="B14">14</xref>]. Much of the information on the effectivenessof surgery for early GI lymphoma is based on limited, retrospective reviewsthat do not specifically compare primary surgical therapy with primary medical management are either chemotherapy, radiotherapy, or radiochemotherapy.</p><p>Regardless of surgical resection, the overall 5-year survival rate for smallbowel cancers ranges between 20 and 50% [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. Their disappointingcourse seems to be related to the delay in diagnosis because of the nonspecificsymptoms [<xref ref-type="bibr" rid="B8">8</xref>]. In our study, the 5-year survival rates of GIST (50%) were higherthan those of adenocarcinomas and lymphomas and are close to the 67% 5-yearsurvival reported by Egberts et al. [<xref ref-type="bibr" rid="B16">16</xref>]. Therefore, early surgicalintervention with a high index of suspicion is required to improve survival[<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Given the low prevalence of this disease, few clinicaltrials of chemotherapy have been conducted and despite a variety ofchemotherapeutic agents used to treat adenocarcinoma of the small bowel, nostandard chemotherapy regimen exists for this disease. Many oncologistsextrapolate information from trials of large bowel carcinomas or uppergastrointestinal tumors, and apply similar chemotherapy regimens in thetreatment of advanced small bowel adenocarcinoma. In one of the largestretrospective reviews conducted, the M. D. Anderson Cancer Center (Tex, USA) reviewed217 patients with small bowel adenocarcinoma and showed that the use ofadjuvant chemotherapy administered to 59 patients had no survival benefit [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The mostimportant limitation in our study is the small number of patients. This haslimited our ability to determine the significance of the difference in survivalamong the various groups.</p><p>Insummary, small bowel tumors are uncommon. They are difficult to diagnosebecause of the nonspecific symptoms. They also have a poor prognosis becausemost patients present with advanced disease. In our report, adenocarcinoma andduodenal location showed the worst 5-year survival, while stromal tumors andileal location had the best 5-year survival.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="book"><collab>American Joint Committee on Cancer</collab><article-title>Small intestine</article-title><source><italic>AJCC Cancer Staging Manual</italic></source><year>2002</year><edition>6th edition</edition><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Springer</publisher-name><fpage>107</fpage><lpage>112</lpage></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naef</surname><given-names>M</given-names></name><name><surname>B&#x000fc;hlmann</surname><given-names>M</given-names></name><name><surname>Baer</surname><given-names>HU</given-names></name></person-group><article-title>Small bowel tumors: diagnosis, therapy and prognostic factors</article-title><source><italic>Langenbeck's Archives of Surgery</italic></source><year>1999</year><volume>384</volume><issue>2</issue><fpage>176</fpage><lpage>180</lpage></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>JH</given-names></name><name><surname>Pack</surname><given-names>MS</given-names></name></person-group><article-title>Malignant tumors of the small intestine: a review of 144 cases</article-title><source><italic>American Surgeon</italic></source><year>2000</year><volume>66</volume><issue>1</issue><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">10651347</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Treadwell</surname><given-names>TA</given-names></name><name><surname>White</surname><given-names>RR</given-names></name></person-group><article-title>Primary tumors of the small bowel</article-title><source><italic>The American Journal of Surgery</italic></source><year>1975</year><volume>130</volume><issue>6</issue><fpage>749</fpage><lpage>755</lpage></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name><name><surname>Neugut</surname><given-names>AI</given-names></name></person-group><article-title>A population-based study of the incidence of malignant small bowel tumours: SEER, 1973&#x02013;1990</article-title><source><italic>International Journal of Epidemiology</italic></source><year>1996</year><volume>25</volume><issue>4</issue><fpage>722</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">8921448</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dabaja</surname><given-names>BS</given-names></name><name><surname>Suki</surname><given-names>D</given-names></name><name><surname>Pro</surname><given-names>B</given-names></name><name><surname>Bonnen</surname><given-names>M</given-names></name><name><surname>Ajani</surname><given-names>J</given-names></name></person-group><article-title>Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>101</volume><issue>3</issue><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">15274064</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Talamonti</surname><given-names>MS</given-names></name><name><surname>Goetz</surname><given-names>LH</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Joehl</surname><given-names>RJ</given-names></name></person-group><article-title>Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management</article-title><source><italic>Archives of Surgery</italic></source><year>2002</year><volume>137</volume><issue>5</issue><fpage>564</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">11982470</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DiSario</surname><given-names>JA</given-names></name><name><surname>Burt</surname><given-names>RW</given-names></name><name><surname>Vargas</surname><given-names>H</given-names></name><name><surname>McWhorter</surname><given-names>WP</given-names></name></person-group><article-title>Small bowel cancer: epidemiological and clinical characteristics from a population-based registry</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>1994</year><volume>89</volume><issue>5</issue><fpage>699</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">8172140</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serour</surname><given-names>F</given-names></name><name><surname>Dona</surname><given-names>G</given-names></name><name><surname>Birkenfeld</surname><given-names>S</given-names></name><name><surname>Balassiano</surname><given-names>M</given-names></name><name><surname>Krispin</surname><given-names>M</given-names></name></person-group><article-title>Primary neoplasms of the small bowel</article-title><source><italic>Journal of Surgical Oncology</italic></source><year>1992</year><volume>49</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">1548877</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>RC</given-names></name><name><surname>Welch</surname><given-names>CE</given-names></name><name><surname>Malt</surname><given-names>RA</given-names></name></person-group><article-title>Adenocarcinoma and lymphoma of the small intestine. Distribution and etiologic associations</article-title><source><italic>Annals of Surgery</italic></source><year>1983</year><volume>197</volume><issue>2</issue><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">6337568</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>JH</given-names></name></person-group><article-title>Malignant tumours of the small bowel</article-title><source><italic>Surgical Oncology</italic></source><year>1994</year><volume>3</volume><issue>2</issue><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">7952393</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kusumoto</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>I</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><etal/></person-group><article-title>Primary malignant tumors of the small intestine: analysis of 40 Japanese patients</article-title><source><italic>Journal of Surgical Oncology</italic></source><year>1992</year><volume>50</volume><issue>3</issue><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">1619934</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ripley</surname><given-names>D</given-names></name><name><surname>Weinerman</surname><given-names>BH</given-names></name></person-group><article-title>Increased incidence of second malignancies associated with small bowel adenocarcinoma</article-title><source><italic>Canadian Journal of Gastroenterology</italic></source><year>1997</year><volume>11</volume><issue>1</issue><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">9113802</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>JD</given-names></name><name><surname>Aleali</surname><given-names>R</given-names></name><name><surname>Aleali</surname><given-names>M</given-names></name><name><surname>Brower</surname><given-names>ST</given-names></name><name><surname>Aufses</surname><given-names>AH</given-names></name></person-group><article-title>Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival</article-title><source><italic>Annals of Surgery</italic></source><year>1997</year><volume>225</volume><issue>3</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">9060587</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ojha</surname><given-names>A</given-names></name><name><surname>Zacherl</surname><given-names>J</given-names></name><name><surname>Scheuba</surname><given-names>C</given-names></name><name><surname>Jakesz</surname><given-names>R</given-names></name><name><surname>Wenzl</surname><given-names>E</given-names></name></person-group><article-title>Primary small bowel malignancies: single-center results of three decades</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2000</year><volume>30</volume><issue>3</issue><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">10777190</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egberts</surname><given-names>J-H</given-names></name><name><surname>Scharrer</surname><given-names>M-L</given-names></name><name><surname>Hinz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Small bowel cancer: single-centre results over a period of 12 years</article-title><source><italic>Hepato-Gastroenterology</italic></source><year>2007</year><volume>54</volume><issue>73</issue><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">17419246</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>MH</given-names></name><name><surname>Barben</surname><given-names>CP</given-names></name><name><surname>Eu</surname><given-names>KW</given-names></name><name><surname>Seow-Choen</surname><given-names>F</given-names></name></person-group><article-title>Small bowel malignancies: a review of 29 patients at a single centre</article-title><source><italic>Colorectal Disease</italic></source><year>2004</year><volume>6</volume><issue>3</issue><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15109386</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patient characteristics and clinical presentation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">No. of patients</th><th align="center" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x0003c;50</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">(33.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic> &#x02265;50</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(66.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Male</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">(75.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Female</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">(24.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Symptom</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Abdominal pain</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(66.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Weight loss</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">(57.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Nausea/vomiting</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">(27.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Bowel obstruction</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">(24.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>GI bleeding</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">(24.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Anemia</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">(21.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Bowel perforation</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(12.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Acute abdomen</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(12.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Jaundice</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(12.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Constipation</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(9.0)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Distribution of small bowel tumors by pathology and anatomical distribution.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Duodenum</th><th align="center" rowspan="1" colspan="1">Jejunum</th><th align="center" rowspan="1" colspan="1">Ileum</th><th align="center" rowspan="1" colspan="1">No. (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lymphoma</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">12 (36.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">11 (33)</td></tr><tr><td align="left" rowspan="1" colspan="1">Leiomyosarcoma</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">5 (15.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">GIST*</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuroendocrine</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total(%)</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">33</td></tr></tbody></table></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Treatment modalities offered to 33 patients with small bowel tumors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Modality</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No treatment</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">12.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete resection</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">36.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete resection + chemotherapy</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">18.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Incomplete resection</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">12.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Incomplete resection + chemotherapy</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemotherapy (palliative)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">15.1</td></tr></tbody></table></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Types of surgeries performed for small intestine tumors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Surgery</th><th align="center" rowspan="1" colspan="1">No. of patients (26)</th><th align="center" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Whipple</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">(16.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duodenal resection</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(6.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Jejunal resection</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">(30)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ileal resection</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">(16.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Right hemicolectomy</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(10)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bypass</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(6.6)</td></tr></tbody></table></table-wrap><table-wrap id="tab5" position="float"><label>Table 5</label><caption><p>TNM staging of small bowel malignancies, excluding lymphoma. (Adapted from the AJCC Cancer Staging Manual, 6th Edition (2002), Springer New York).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Stage</th><th align="center" rowspan="1" colspan="1">Primary tumor<sup>1</sup></th><th align="center" rowspan="1" colspan="1">Regional lymph nodes<sup>2</sup></th><th align="center" rowspan="1" colspan="1">Distant metastasis<sup>3</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">T1/T2</td><td align="center" rowspan="1" colspan="1">N0</td><td align="center" rowspan="1" colspan="1">M0</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">T3/T4</td><td align="center" rowspan="1" colspan="1">N0</td><td align="center" rowspan="1" colspan="1">M0</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Any T</td><td align="center" rowspan="1" colspan="1">N1</td><td align="center" rowspan="1" colspan="1">M0</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">Any T</td><td align="center" rowspan="1" colspan="1">Any N</td><td align="center" rowspan="1" colspan="1">M1</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>1</sup>Primary tumor</p><p>T1: tumor invades lamina propria or submucosa;</p><p>T2: tumor invades muscularis propria;</p><p>T3: tumor invades through muscularis propria into the subserosa;</p><p>T4: tumor perforates the vascular peritoneum or directly invades other organs, including mesentery, abdominal wall, and pancreas.</p><p>						<sup>2</sup>Regional lymph nodes</p><p>N0: no regional lymph nodes metastasis;</p><p>N1: regional lymph nodes metastasis.</p><p>						<sup>3</sup>Distant metastasis</p><p>M0: no distant metastasis;</p><p>M1: distant metastasis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" position="float"><label>Table 6</label><caption><p>Stage and grade of small bowel tumors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Grade </th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Well</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">(15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Poor</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(12)</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">(64)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(6)</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">(27)</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">(24)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">(21)</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">(21)</td></tr></tbody></table></table-wrap><table-wrap id="tab7" position="float"><label>Table 7</label><caption><p>Survival of small intestine tumors at 1, 3, and 5 years by location.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">1 year (%)</th><th align="center" rowspan="1" colspan="1">3 years (%)</th><th align="center" rowspan="1" colspan="1">5 years (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Duodenum</td><td align="center" rowspan="1" colspan="1">50%</td><td align="center" rowspan="1" colspan="1">40%</td><td align="center" rowspan="1" colspan="1">10%</td></tr><tr><td align="left" rowspan="1" colspan="1">Jejunum</td><td align="center" rowspan="1" colspan="1">50%</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">20%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ileum</td><td align="center" rowspan="1" colspan="1">62.5%</td><td align="center" rowspan="1" colspan="1">37.5%</td><td align="center" rowspan="1" colspan="1"><bold>37.5</bold>%						</td></tr></tbody></table></table-wrap><table-wrap id="tab8" position="float"><label>Table 8</label><caption><p>Survival of small intestine tumors at 1, 3, and 5 years by histology.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">1 year (%)</th><th align="center" rowspan="1" colspan="1">3 years (%)</th><th align="center" rowspan="1" colspan="1">5 years (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">30%</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">10%</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphoma</td><td align="center" rowspan="1" colspan="1">36.4%</td><td align="center" rowspan="1" colspan="1">27.3%</td><td align="center" rowspan="1" colspan="1">18.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Leiomyosarcoma</td><td align="center" rowspan="1" colspan="1">60%</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">20%</td></tr><tr><td align="left" rowspan="1" colspan="1">GIST</td><td align="center" rowspan="1" colspan="1">100%</td><td align="center" rowspan="1" colspan="1">75%</td><td align="center" rowspan="1" colspan="1"><bold>50</bold>%						</td></tr></tbody></table></table-wrap></floats-wrap></article>